Table 8. Multivariate Cox proportional hazards analysis of survival factors in the F2 mutation group.
| Characteristic | HR | 95% CI | p-value |
|---|---|---|---|
| Age_at_diagnosis | 1 | 0.99, 1.01 | >0.9 |
| Gender | |||
| Female | — | — | |
| Male | 0.96 | 0.78, 1.18 | 0.7 |
| Race_new | |||
| White | — | — | |
| Black or African American | 1.06 | 0.79, 1.41 | 0.7 |
| Other | 1.39 | 0.98, 1.96 | 0.065 |
| Stage | |||
| Stage I | — | — | |
| Stage II | 1.85 | 1.46, 2.35 | <0.001 |
| Stage III | 2.19 | 1.68, 2.84 | <0.001 |
| Stage IV | 1.6 | 1.02, 2.50 | 0.04 |
| Tissue_or_organ_of_origin | |||
| Lower lobe, lung | — | — | |
| Lung, NOS | 0.88 | 0.53, 1.45 | 0.6 |
| Middle lobe, lung | 1.33 | 0.81, 2.19 | 0.3 |
| Upper lobe, lung | 1.2 | 0.97, 1.49 | 0.092 |
| Treatment_type2 | |||
| Chemotherapy | — | — | |
| Ancillary Treatment | 1.11 | 0.26, 4.79 | 0.9 |
| Immunotherapy (Including Vaccines) | 1.5 | 0.47, 4.83 | 0.5 |
| Pleurodesis, NOS | — | — | |
| Radiation | 0.86 | 0.68, 1.09 | 0.2 |
| Targeted Therapy | 0.86 | 0.66, 1.12 | 0.3 |
| Laterality | |||
| Left | — | — | |
| Right | 1.24 | 1.01, 1.51 | 0.04 |
| Counts | 1.07 | 1.00, 1.14 | 0.051 |
Survival analysis in F2 mutation group (Multivariable).